HHZ Respiratory Review

Fixed-pressure CPAP in India: When It’s Still Right (2026)

APAP has displaced fixed-pressure CPAP as the default prescription for new OSA patients in India. That is the right clinical trend. But “displaced as the default” is not the same as “obsolete.” There are specific patient presentations for which a fixed-pressure device is still the correct therapy, and there are cost scenarios where a fixed-pressure CPAP is the defensible buy. This guide covers when fixed-pressure CPAP remains clinically appropriate, what the tradeoffs are against APAP, and which machines actually deliver clean fixed-pressure therapy in the 2026 Indian market.

What fixed-pressure CPAP does — and what it doesn’t

A fixed-pressure CPAP delivers a single prescribed pressure all night. If the prescription says 10 cmH₂O, the device runs 10 cmH₂O from mask-on to mask-off, modulated only by expiratory pressure relief (EPR or Flex) if the patient has that feature enabled. There is no auto-titration, no breath-by-breath pressure response to detected events, and no algorithm-driven reactivity.

This is a simpler therapy, and in the narrow range of patients for whom it is appropriate, it is not inferior to APAP. It is the therapy CPAP was designed to be when Sullivan described it in 1981. The shift to APAP is an answer to a set of clinical problems — variable nightly pressure requirements, adherence gaps, the difficulty of booking in-lab titrations — that APAP solves well. In patients who do not have those problems, a fixed-pressure device is a legitimate choice.

What fixed-pressure CPAP does not do: respond to an unexpectedly bad night (alcohol, sinus congestion, weight gain of 2 kg, a shift to REM-heavy sleep) with higher pressure. Does not lower pressure when the airway is stable, meaning average pressure is typically higher than what an APAP would deliver on the same patient. Does not record the breath-by-breath event data that APAPs record, meaning clinician-side insight into residual events and flow limitation is limited to the (sparse) compliance data the device exports.

When fixed-pressure CPAP is still clinically appropriate

Three scenarios justify a fixed-pressure prescription in 2026.

1. Confirmed in-lab titration with a stable single-pressure response. A patient who has undergone overnight in-lab CPAP titration, whose titration curve shows the apnea-hypopnea index collapsing at a specific pressure and remaining suppressed at that pressure across sleep stages and body positions, is a clean candidate for fixed-pressure therapy at that exact titrated pressure. The in-lab titration is, ironically, a much rarer clinical pathway in India in 2026 than it was fifteen years ago, precisely because most Indian sleep centres now discharge patients on auto-titrating APAPs. But for the patient who has had an in-lab titration and has a stable response, a fixed-pressure device delivers the prescribed therapy with minimum complexity.

2. Mild, stable OSA with low pressure requirement. A patient with AHI 8–15, a titrated pressure below 10 cmH₂O, no positional variation, no REM dominance, stable BMI, and no comorbidity is clinically stable on fixed-pressure therapy. The extra complexity of an APAP algorithm is not adding value — the pressure requirement is a flat line all night.

3. Cost-constrained buyers where the alternative is no therapy. This is the uncomfortable but clinically honest scenario. For a patient with moderate OSA who will either buy a ₹17,000 fixed-pressure CPAP or not buy anything, the fixed-pressure CPAP is preferable to no therapy. The therapy may be imperfectly matched to nightly variation, but the adherence harm of having no device at all is worse. This scenario is common in India and clinicians should not moralize about it. Several of the entry-level Indian-manufactured and Chinese-manufactured APAPs in the catalogue can run in fixed-pressure mode if the prescriber chooses, which collapses the economic delta — buy an APAP-capable device and run it at fixed pressure if that is the prescription.

What APAP solves that fixed-pressure does not

It is worth being specific about the failure modes of fixed-pressure therapy, because understanding them is the test for whether a patient is in the narrow band of candidates for whom fixed-pressure is correct.

Positional OSA. Supine-dominant OSA requires a meaningfully higher pressure than side-sleeping OSA. A fixed pressure set to the supine requirement overshoots by 2–4 cmH₂O when the patient rolls onto their side; a fixed pressure set to the lateral requirement produces residual obstructive events when the patient is supine.

REM-predominant OSA. REM sleep deepens airway collapsibility. A patient whose events concentrate in late-night REM needs higher pressure in the last third of the night; a fixed pressure set to the N2 requirement undertreats REM events.

Weight-responsive OSA. A patient losing weight on a diet, or gaining weight off an antidepressant, is on a moving pressure-requirement curve. Fixed-pressure therapy locks in yesterday’s prescription; APAP tracks the shift.

CPAP-induced aerophagia. High fixed pressure in a patient who does not need it on most nights produces air swallowing, morning bloat, and — in a subset — abandonment of therapy. APAP drops to the actual requirement most of the night, which lowers the aerophagia burden.

For a patient who fits any of these profiles, fixed-pressure CPAP is not the right therapy even if it is affordable.

Fixed-pressure-capable machines in the Indian catalogue

Most devices sold as APAPs in the Indian market also support fixed-pressure mode. The buyer’s decision is less often “buy a fixed-pressure-only device” and more often “buy an APAP-capable device and run it at a fixed prescribed pressure.”

ResMed AirSense 10 Elite (fixed-pressure sibling to the AutoSet)

The ResMed AirSense 10 Elite is the fixed-pressure variant of the AirSense 10 platform. It runs only in fixed CPAP mode, uses the same HumidAir heated humidifier, ClimateLineAir heated tube, and AirView data ecosystem as the AutoSet, and is typically priced ₹5,000–₹8,000 below the AutoSet at Indian channel. It is available through authorized ResMed dealers — note that not every e-commerce listing differentiates the Elite from the AutoSet, and some catalogued listings show the AutoSet version only. For a patient whose prescription is explicitly for fixed-pressure CPAP and who wants ResMed build quality and service, the Elite is the intended product.

ResMed AirStart 10 Auto — running in fixed mode

The ResMed AirStart 10 Auto at ₹24,430 supports both APAP and fixed CPAP modes. Published specs: 4–20 cmH₂O pressure range, 26.6 dB, 1.1 kg, heated humidifier, SD card, EPR, 3-year warranty per Indian channel documentation. For a patient with a confirmed titration pressure who wants a simple device with ResMed’s service footprint, this is a reasonable buy — set the fixed pressure and leave the auto functionality unused. The standard-tier algorithm is not being deployed, which matches the use case.

BMC RESmart GII Auto CPAP — running in fixed mode

The BMC RESmart GII Auto CPAP at ₹17,490 is the price-leader for a device that can deliver either APAP or fixed CPAP therapy. Published specs: 4–20 cmH₂O, 30 dB, 2.5 kg, heated humidifier, detachable design, SD card with iCode compliance codes, 2-year warranty. At this price it is the floor of the Indian market. The tradeoffs — the heavier unit, the higher sound level, the thinner data platform — are real, but for a patient whose alternative is no therapy, it is a defensible buy. Set it to fixed-pressure mode at the titrated setting.

Deckmount VT50 — Indian-manufactured option

The Deckmount VT50 at ₹25,919 supports fixed CPAP operation with AFlex-style expiratory relief. Published specs: 4–20 cmH₂O, 28 dB, 1.8 kg, heated humidifier, SD card, QR-code data, made-in-India turbine per manufacturer brochure. For buyers prioritizing Indian manufacture, Indian service reachability, and a fixed-pressure prescription, it is an option. The algorithm is not the question here — a fixed-pressure prescription does not deploy the algorithm.

BPL Harmony Auto — running in fixed mode

The BPL Harmony Auto CPAP at ₹35,519 is Indian-manufactured (BPL Bengaluru) and supports both APAP and fixed CPAP modes. Published specs: 4–20 cmH₂O, 28 dB, 1.55 kg, heated humidifier, SD card, leak compensation, 2-year warranty, DC brushless motor with claimed 20,000-hour service life per manufacturer brochure. BPL’s direct-owned service footprint across Indian cities is one of the better ones in the domestic-manufacture tier, which matters over a 5-year device life.

Philips DreamStation (platform variants)

Philips DreamStation APAPs support fixed-pressure operation. Channel availability in India has been uneven since the 2021 device recall and subsequent remediation. For new buys in 2026, ResMed’s platforms dominate the premium and mid-premium channel. For patients already on a DreamStation who are not affected by the recall and want to continue, the platform supports both modes.

What fixed-pressure CPAP setup looks like in practice

A fixed-pressure prescription from an Indian sleep physician typically reads: CPAP at [X] cmH₂O, heated humidification, full-face or nasal mask per patient tolerance, EPR on or off at prescriber’s discretion. EPR (ResMed) and C-Flex (Philips) are expiratory pressure-relief features that drop the pressure by 1–3 cmH₂O during exhalation to ease the expiratory workload without compromising the inspiratory splint. They are not auto-titration — they are pressure-shaping features — and they are appropriate on fixed-pressure devices.

Setup of the fixed prescription is performed by the dealer or the prescribing clinician via the device’s clinician menu (PIN-protected on most platforms). Patients should not set fixed pressure themselves; the prescription figure is load-bearing.

The titration report — what to read before buying fixed-pressure

For a patient considering fixed-pressure CPAP based on a past titration report, the specific data points that determine whether a single fixed pressure is actually appropriate:

Pressure convergence across sleep stages. The titration summary typically tables residual AHI at different pressure levels for N1/N2, N3, and REM. If the pressure at which AHI collapses in REM matches the pressure for N2 and N3 (within 1–2 cmH₂O), the airway is relatively stage-invariant and fixed pressure is defensible. If REM elimination requires 3+ cmH₂O more than N2 elimination, the patient is stage-variable and fixed pressure will under-treat REM events all night — APAP is the better match.

Positional data. Many Indian titration reports include supine vs lateral breakdown. If the supine-eliminating pressure is 2+ cmH₂O above the lateral-eliminating pressure, the patient is positional — fixed pressure either over-pressurizes laterally or under-treats supine. APAP handles this; fixed pressure compromises in both directions.

Leak profile at the titrated pressure. A titration done at 12 cmH₂O with mean leak 18 L/min is acceptable; a titration at 14 cmH₂O with mean leak 36 L/min is not — the mask-fit is problematic and the real required pressure may be higher than the titration suggested. Fixed-pressure therapy on a bad mask-fit foundation will fail regardless of device quality.

Central apnea index on the titration night. If the titration showed CSA emerging at higher pressures (treatment-emergent central apnea), CPAP at any pressure is not the right therapy — the patient needs BiPAP-ST or ASV. Confirm this is not what the report shows before proceeding with fixed-pressure CPAP.

Time-to-titration. If the titration night took several hours to find the right pressure and the final pressure was held for less than 2 hours, the titration is weakly supported — a subsequent APAP’s auto-titration over 2–4 weeks is arguably more reliable than the fixed prescription derived from a short stable window.

Indian titration reports vary in the thoroughness with which they document these fields. A report that names only “titrated pressure: 10 cmH₂O” without the stage and position breakdown should be treated skeptically for purposes of committing to fixed-pressure therapy. Push back to the sleep lab for the detailed summary; it is the basis of the prescription.

Fixed-pressure in specific Indian patient populations

Several Indian patient populations have context-specific considerations for the fixed-vs-APAP decision:

Rural and small-town buyers far from service centres. A fixed-pressure device has fewer moving parts algorithmically — fewer pressure sensors being driven at the limits of their spec, fewer cycles of the high-sensitivity flow sensors — and therefore typically has a modestly longer mean-time-between-failures on the pressure-sensing subsystem. This is not a huge effect but it is real. For patients 150+ km from the nearest authorized service centre, the simplicity of fixed-pressure reduces the probability of in-warranty service events.

Shared-device family setups. Some Indian buyers (for cost reasons) try to use one device across multiple family members with similar prescriptions. This is clinically inadvisable at any pressure — mask hygiene, humidifier contamination, and compliance data contamination — but it does happen. Fixed-pressure devices are easier to share in the limited sense that the prescription does not auto-drift per user. APAP auto-titration data becomes meaningless when the device is shuffled between users with different physiology. If a family is determined to share a device anyway (again, not recommended), fixed-pressure at a conservative pressure (e.g., 10 cmH₂O) is marginally less confusing than APAP.

Patients on concurrent BiPAP indications in the household. In a household where a spouse or parent is on BiPAP-ST and the OSA patient is on CPAP, standardizing on a single dealer and brand simplifies the consumables supply chain, service relationships, and voltage-stabilizer specifications. ResMed’s device ecosystem spans both with interchangeable masks and humidifier accessories; BMC’s does too. This is a secondary factor but worth considering.

Monsoon-zone humidity management. In Kerala, coastal Karnataka, coastal Odisha, and similar humidity belts, the heated humidifier on a fixed-pressure CPAP can produce rainout (condensate in the tube) more often than on an APAP because the average pressure is higher. Heated tube accessories (where available — ResMed ClimateLineAir, Philips Heated Tube) largely eliminate this. For fixed-pressure users in humidity zones, buying the heated tube is not optional if available on the platform.

Voltage and service considerations specific to India

Fixed-pressure CPAPs are simpler devices — fewer pressure sensors, fewer processor cycles per second, less algorithmic overhead — and as a rule they are slightly more voltage-tolerant than the premium APAPs. That said, every CPAP sold in India should be paired with a servo-regulated voltage stabilizer rated for the device wattage (65–100 W typically), priced ₹1,200–₹2,500. The grid variance in much of the country routinely excursions outside the 180–264 V AC tolerance window of imported CPAPs, and a blown power supply on an out-of-warranty unit costs ₹8,000–₹18,000 to replace depending on the brand.

For humid-belt cities (Mumbai, Chennai, Kolkata, the Kerala coast), heated humidification is effectively mandatory year-round, which pushes the device’s power draw toward the upper end of its spec. For dry North Indian winters, the humidifier is what prevents the upper-airway dryness that kills adherence. The humidifier is not optional in Indian practice.

When to upgrade from fixed to APAP

There are three triggers that should prompt a fixed-pressure patient to upgrade to APAP:

If any of those triggers is present, the fixed-pressure device has served its purpose and the patient should move to an APAP. See our APAP buyer’s guide for the next step.

Final recommendation

For the three scenarios where fixed-pressure CPAP is clinically correct — confirmed in-lab titration, mild stable OSA with low pressure requirement, and cost-constrained buyers with no APAP path — buy an APAP-capable device and run it at a fixed prescribed pressure. The cost delta between fixed-only and APAP-capable devices in the Indian market is small enough that the optionality is worth the spend.

If budget is the hard constraint and ₹17,000 is the ceiling, the BMC RESmart GII Auto CPAP is the floor of what is defensible. If budget allows ₹25,000–₹30,000, the Oxymed SleepEasy AutoCPAP brings 3-year PAN-India home service that materially changes the ownership experience.

If the patient has any of the indications that argue for APAP — positional OSA, REM-dominant events, weight variability, CPAP-induced aerophagia on a past trial — stop reading this guide and go to the APAP guide. Fixed-pressure is not the right therapy for those patients and the cost saving does not justify the clinical mismatch.

If the patient has central events, hypercapnia, or any ventilation indication, neither fixed-pressure CPAP nor APAP is appropriate — go to our BiPAP ST or TVAPS guides.